<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779987</url>
  </required_header>
  <id_info>
    <org_study_id>AP261</org_study_id>
    <nct_id>NCT00779987</nct_id>
  </id_info>
  <brief_title>Autologous Serum Efficacy Study in Patients With Severe Dry Eye</brief_title>
  <official_title>Autologous Serum Efficacy Study in Patients With Severe Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the reduction in symptomatology of patients with
      severe dry eye treated with autologous serum and conventional artificial tears.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe dry eye remains an important and frequent eye disease, that reflects in a severe
      impairment of the patient´s life quality. Up to date there is no ideal therapy for this
      condition. Few studies have reported some kind of improvement in different parameters related
      to dry eye with the use of autologous serum, but no one has considered the patient´s symptoms
      with a systematic and validated evaluation method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the score reduction in the Ocular Surface Disease Index (OSDI) between patients treated with autologous serum and conventional artificial tears.</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare variations in objective eye measurements, such as Tear Break Up Time and corneal-conjunctival staining according to the Oxford Score, in patients treated with autologous serum and conventional artificial tears.</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Autologous serum -Systane</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane- Autologous serum</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous serum - Systane</intervention_name>
    <description>20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.</description>
    <arm_group_label>Autologous serum -Systane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane - Autologous serum</intervention_name>
    <description>Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.</description>
    <arm_group_label>Systane- Autologous serum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Severe Dry Eye, as defined by a OSDI score &gt; or = 40

        Plus:

          -  Tear Break Up Time (TBUT) &lt; 5 seconds

          -  Cornea-conjunctival epithelial defects measured by Fluorescein staining and evaluation
             using the Oxford score.

        Exclusion Criteria:

          -  No dry eye associated ocular disease

          -  Unable to comply protocol

          -  Severe anemia

          -  Previous use of autologous serum

          -  Concomitant use of other topical ocular drug

          -  Hypersensibility to any proposed interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristhian A Urzua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Chile Clinical Hospital</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cristhian A Urzua</name_title>
    <organization>University of Chile</organization>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>Autologous serum</keyword>
  <keyword>Ocular Surface Disease Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

